Paul Anderson | Bastyr University (original) (raw)
Uploads
Papers by Paul Anderson
Supportive therapies incorporating autologous stem cells and natural agents. Part 2 of 2.
Supportive therapies incorporating autologous stem cells and natural agents. Part 1 of 2.
Townsend Letter, 2018
In 2009 as part of a “non-responder” arm of an NIH funded trial we (7) surmised a potential syner... more In 2009 as part of a “non-responder” arm of an NIH funded trial we (7) surmised a potential synergy of Diet changes, Dichloroacetate (DCA) + PolyMVA (LAMC) with Hyperbaric Oxygen (HBOT), Retinoids and exogenous ketones. A cell line study (1,8) with DCA and LAMC showed apoptotic cell synergy in GBM cells. Additionally chemically the two agents have a potential for physiologic mutual benefit in that typical DCA use requires cell protective support during treatment and LAMC has been shown to be neuroprotective and supportive to the mitochondrial complex. (2,3,4,5) The author had used DCA with supportive nutrients prior to this and abandoned its use due to a high side effect profile. Concurrent to the above we also began to add ketogenic and HBOT interventions as suggested in some data. (12) This is our updated clinical protocol outline based on the synthesis of this information in humans.
Intravenously administered high dose ascorbic acid (HDIVC) as used in cases of patients who have ... more Intravenously administered high dose ascorbic acid (HDIVC) as used in cases of patients who have cancer has considerable mythology surrounding it. The purpose of this review is not to exhaustively recap the data regarding this therapy but rather to address basic issues of safety, pharmacology and outcomes of ongoing research.
A rational and safe combination therapy using DCA and support LAMC in advanced cancers. Based on... more A rational and safe combination therapy using DCA and support LAMC in advanced cancers. Based on a cell line study showing synergy a small human case series was initiated. Positive results in non responsive cancers was shown.
Lipoic Acid Mineral Complex (LAMC also known as "PolyMVA") is a redox molecule that facilitates e... more Lipoic Acid Mineral Complex (LAMC also known as "PolyMVA") is a redox molecule that facilitates energy charge transfer at the cellular level with regards to the cellular transport chain, it can therefore protect and provide energy. Mimics the electron transport chain. Differs from free radical scavengers (e.g. alpha-lipoic acid) since there is no free lipoic acid or palladium. They are irreversibly bound together resulting in a molecule that is both fat and water soluble. LAMC (brand name in North America: Poly-MVA, also referred to as Pd-LA) is a polymer (liquid crystal) rather than a single molecule. Therefore, the polymer provides a unified redox reaction. In summary it is an extremely effective energy transferring molecule. LAMC has been shown to be neuroprotective and helpful in supporting the mitochondrial complex.
Intravenous curcumin is a novel and promising adjunct to the care of the cancer and chronically i... more Intravenous curcumin is a novel and promising adjunct to the care of the cancer and chronically ill patient population. Oral administration has been shown to provide some benefit, but absorption and distribution kinetics do not always allow maximal benefit.
A review of over forty peer-reviewed publications by the author as well as personal use of intravenous preparations of curcumin yields this summary and rationale for the use of intravenous curcumin.
Artemisia based medications are used the world over for anti-malarial activity. Their pharmacolo... more Artemisia based medications are used the world over for anti-malarial activity. Their pharmacology and safety are well studied and published in the scientific literature. The use of these agents in the patient with cancer and their effectiveness against cancer cell lines are newer areas of scientific research, but also published in the literature. Experience in our clinical research of over one thousand parenteral doses of Artesunate have shown this agent to be safe in patients with advanced cancers, infectious diseases and autoimmunity. While specific human clinical data needs to be collected our experience and the basic pharmacology of artesunate in cancer lead us to the conclusion that this agent is worthy of further investigation in oncology and chronic illness practice.
In an interventional study associated with BIORC and AMSA we attempted to answer the questions re... more In an interventional study associated with BIORC and AMSA we attempted to answer the questions regarding electrolyte shifts and HDIVC administration.
Objectives: MTHFR defects are known to include a large portion of the healthy human population. T... more Objectives:
MTHFR defects are known to include a large portion of the healthy human population. The aim of this study is to determine if the incidence of MTHFR defect in the CFS/FMS population is different than the general population, and if specific intervention to treat such defects improves outcomes over standard integrative naturopathic therapy this population.
Design:
Active comparator trial
Measures:
Laboratory analysis of 88 previously diagnosed CFS/FMS patients as compared to population matched controls.
Results:
Incidence of the medically correlated gene variants for MTHFR (C677T and A1298C) in the total population are estimated to be between 36 – 49 % for heterozygotes, 10-12% for homozygotes and 10-20% for compound heterozygotes [1,2,4]. While Harmon DL, et.al. [3] originally published no correlation between CFS and a higher incidence in MTHFR variation in 1997 our clinical experience seemed to point to a different correlation. We selected 88 patients with a prior diagnosis of FMS or CFS (based on commonly accepted diagnostic criteria) and tested them for the C677T and A1298C gene variants. We then treated them in a manner consistent with an active comparator trial based on their MTHFR status and compared their therapeutic outcomes after the addition of MTHFR specific therapy to the standard integrative naturopathic therapy they had been receiving.
Conclusions:
MTHFR incidence in the CFS/FMS patient was significantly higher than general population averages with a different distribution of gene defect patterns. The addition of MTHFR specific therapy based on lab findings yielded a significant improvement in outcome as compared to the standard integrative naturopathic therapy in an active comparator trial. These data underscore the importance of proper diagnosis and management of the MTHFR defect group in the CFS/FMS patient population.
Intravenous ascorbate has been used in oncology practice by naturopathic and alternative allopath... more Intravenous ascorbate has been used in oncology practice by naturopathic and alternative allopathic physicians for decades. Published data regarding this therapy shows that it continues to be one of the most commonly employed alternative IV therapies. This popularity has both stimulated awareness of this therapy and concern regarding not only the safety and efficacy of IVAA in the oncology patient but also for the potential of antagonistic reactions with standard therapies.
Publications regarding the postulated mechanisms of action, safety profile, pharmacokinetics and pharmacodynamics were sparse for many years. This led to a highly varied understanding as well as application of IVAA in oncology. In the past five, and especially two, years published data has supported many of the postulated actions of IVC, its pharmacokinetics and dynamics and particularly how those kinetic and dynamic properties can antagonize or synergize the effects of various chemotherapy agents as well as radiation therapies. This data will be presented and summarized.
The goal of this publication is to summarize and update our understanding of the science and practice surrounding this popular and potentially powerful therapeutic agent and how it may interact with standard oncology therapies.
The initial presentation of this basic data was made in February 2013 and the appropriate citation is:
Anderson P. “Intravenous Ascorbic Acid and Oncology Agents.” Scientific Presentation. Oncology Association of Naturopathic Physicians Second Annual Meeting. Phoenix, Arizona. February, 2013.
Conference Presentations by Paul Anderson
This is a presentation of support of concept work using cofactors to augment the activity of glut... more This is a presentation of support of concept work using cofactors to augment the activity of glutathione therapy in a radiation damaged patient model.
Teaching Documents by Paul Anderson
IV Nutrient therapies can be used in series in many instances. This chart was developed for use ... more IV Nutrient therapies can be used in series in many instances. This chart was developed for use in research clinics and outpatient centers to aid in proper administration of IV therapies within the same day or clinical shift.
Supportive therapies incorporating autologous stem cells and natural agents. Part 2 of 2.
Supportive therapies incorporating autologous stem cells and natural agents. Part 1 of 2.
Townsend Letter, 2018
In 2009 as part of a “non-responder” arm of an NIH funded trial we (7) surmised a potential syner... more In 2009 as part of a “non-responder” arm of an NIH funded trial we (7) surmised a potential synergy of Diet changes, Dichloroacetate (DCA) + PolyMVA (LAMC) with Hyperbaric Oxygen (HBOT), Retinoids and exogenous ketones. A cell line study (1,8) with DCA and LAMC showed apoptotic cell synergy in GBM cells. Additionally chemically the two agents have a potential for physiologic mutual benefit in that typical DCA use requires cell protective support during treatment and LAMC has been shown to be neuroprotective and supportive to the mitochondrial complex. (2,3,4,5) The author had used DCA with supportive nutrients prior to this and abandoned its use due to a high side effect profile. Concurrent to the above we also began to add ketogenic and HBOT interventions as suggested in some data. (12) This is our updated clinical protocol outline based on the synthesis of this information in humans.
Intravenously administered high dose ascorbic acid (HDIVC) as used in cases of patients who have ... more Intravenously administered high dose ascorbic acid (HDIVC) as used in cases of patients who have cancer has considerable mythology surrounding it. The purpose of this review is not to exhaustively recap the data regarding this therapy but rather to address basic issues of safety, pharmacology and outcomes of ongoing research.
A rational and safe combination therapy using DCA and support LAMC in advanced cancers. Based on... more A rational and safe combination therapy using DCA and support LAMC in advanced cancers. Based on a cell line study showing synergy a small human case series was initiated. Positive results in non responsive cancers was shown.
Lipoic Acid Mineral Complex (LAMC also known as "PolyMVA") is a redox molecule that facilitates e... more Lipoic Acid Mineral Complex (LAMC also known as "PolyMVA") is a redox molecule that facilitates energy charge transfer at the cellular level with regards to the cellular transport chain, it can therefore protect and provide energy. Mimics the electron transport chain. Differs from free radical scavengers (e.g. alpha-lipoic acid) since there is no free lipoic acid or palladium. They are irreversibly bound together resulting in a molecule that is both fat and water soluble. LAMC (brand name in North America: Poly-MVA, also referred to as Pd-LA) is a polymer (liquid crystal) rather than a single molecule. Therefore, the polymer provides a unified redox reaction. In summary it is an extremely effective energy transferring molecule. LAMC has been shown to be neuroprotective and helpful in supporting the mitochondrial complex.
Intravenous curcumin is a novel and promising adjunct to the care of the cancer and chronically i... more Intravenous curcumin is a novel and promising adjunct to the care of the cancer and chronically ill patient population. Oral administration has been shown to provide some benefit, but absorption and distribution kinetics do not always allow maximal benefit.
A review of over forty peer-reviewed publications by the author as well as personal use of intravenous preparations of curcumin yields this summary and rationale for the use of intravenous curcumin.
Artemisia based medications are used the world over for anti-malarial activity. Their pharmacolo... more Artemisia based medications are used the world over for anti-malarial activity. Their pharmacology and safety are well studied and published in the scientific literature. The use of these agents in the patient with cancer and their effectiveness against cancer cell lines are newer areas of scientific research, but also published in the literature. Experience in our clinical research of over one thousand parenteral doses of Artesunate have shown this agent to be safe in patients with advanced cancers, infectious diseases and autoimmunity. While specific human clinical data needs to be collected our experience and the basic pharmacology of artesunate in cancer lead us to the conclusion that this agent is worthy of further investigation in oncology and chronic illness practice.
In an interventional study associated with BIORC and AMSA we attempted to answer the questions re... more In an interventional study associated with BIORC and AMSA we attempted to answer the questions regarding electrolyte shifts and HDIVC administration.
Objectives: MTHFR defects are known to include a large portion of the healthy human population. T... more Objectives:
MTHFR defects are known to include a large portion of the healthy human population. The aim of this study is to determine if the incidence of MTHFR defect in the CFS/FMS population is different than the general population, and if specific intervention to treat such defects improves outcomes over standard integrative naturopathic therapy this population.
Design:
Active comparator trial
Measures:
Laboratory analysis of 88 previously diagnosed CFS/FMS patients as compared to population matched controls.
Results:
Incidence of the medically correlated gene variants for MTHFR (C677T and A1298C) in the total population are estimated to be between 36 – 49 % for heterozygotes, 10-12% for homozygotes and 10-20% for compound heterozygotes [1,2,4]. While Harmon DL, et.al. [3] originally published no correlation between CFS and a higher incidence in MTHFR variation in 1997 our clinical experience seemed to point to a different correlation. We selected 88 patients with a prior diagnosis of FMS or CFS (based on commonly accepted diagnostic criteria) and tested them for the C677T and A1298C gene variants. We then treated them in a manner consistent with an active comparator trial based on their MTHFR status and compared their therapeutic outcomes after the addition of MTHFR specific therapy to the standard integrative naturopathic therapy they had been receiving.
Conclusions:
MTHFR incidence in the CFS/FMS patient was significantly higher than general population averages with a different distribution of gene defect patterns. The addition of MTHFR specific therapy based on lab findings yielded a significant improvement in outcome as compared to the standard integrative naturopathic therapy in an active comparator trial. These data underscore the importance of proper diagnosis and management of the MTHFR defect group in the CFS/FMS patient population.
Intravenous ascorbate has been used in oncology practice by naturopathic and alternative allopath... more Intravenous ascorbate has been used in oncology practice by naturopathic and alternative allopathic physicians for decades. Published data regarding this therapy shows that it continues to be one of the most commonly employed alternative IV therapies. This popularity has both stimulated awareness of this therapy and concern regarding not only the safety and efficacy of IVAA in the oncology patient but also for the potential of antagonistic reactions with standard therapies.
Publications regarding the postulated mechanisms of action, safety profile, pharmacokinetics and pharmacodynamics were sparse for many years. This led to a highly varied understanding as well as application of IVAA in oncology. In the past five, and especially two, years published data has supported many of the postulated actions of IVC, its pharmacokinetics and dynamics and particularly how those kinetic and dynamic properties can antagonize or synergize the effects of various chemotherapy agents as well as radiation therapies. This data will be presented and summarized.
The goal of this publication is to summarize and update our understanding of the science and practice surrounding this popular and potentially powerful therapeutic agent and how it may interact with standard oncology therapies.
The initial presentation of this basic data was made in February 2013 and the appropriate citation is:
Anderson P. “Intravenous Ascorbic Acid and Oncology Agents.” Scientific Presentation. Oncology Association of Naturopathic Physicians Second Annual Meeting. Phoenix, Arizona. February, 2013.
This is a presentation of support of concept work using cofactors to augment the activity of glut... more This is a presentation of support of concept work using cofactors to augment the activity of glutathione therapy in a radiation damaged patient model.
IV Nutrient therapies can be used in series in many instances. This chart was developed for use ... more IV Nutrient therapies can be used in series in many instances. This chart was developed for use in research clinics and outpatient centers to aid in proper administration of IV therapies within the same day or clinical shift.